software

A study of gene expression data from 173 breast cancer patients identified subtype-specific associations between molecular processes in tumor and blood cells. 

The British CRISPR software developer is turning to investment platform SyndicateRoom as it looks to commercialize its products and expand into the US.

The new distributor of DNAStar sequencing analysis software in Japan is a longtime partner of the Wisconsin software company.

The open-source MultiQC software platform aggregates multiple bioinformatics analyses into a single report for the purpose of quality control.

A CIO panel discussed why genomics IT is prepared for new security challenges and why organizations need to step up staff training and retention strategies.

The company is integrating its newly purchased LIMS and genome interpretation and reporting capabilities to provide a single platform for cancer and inherited disease diagnostics.

The Pinnacle assay for gene fusions and gene expression in tumor samples is the first in Cofactor's new line of clinical RNA-sequencing assays.

As PierianDx grows, two customers weighed in on their experiences with the core product, the Clinical Genomicist Workspace, and its NGS-related services.

A new user-friendly software tool is helping Rory Johnson of the University of Bern to do genome-wide screening of lncRNA function by deleting promoters.

The activity follows a recent financing round that has enabled OncoDNA to build out its sales team as it courts new clients.

Pages

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.